2. Academic Validation
  3. Design, Synthesis, and Biological Evaluation of the Novel Neutrophil Elastase Inhibitor CHF-6333 for the Inhaled Treatment of Bronchiectasis

Design, Synthesis, and Biological Evaluation of the Novel Neutrophil Elastase Inhibitor CHF-6333 for the Inhaled Treatment of Bronchiectasis

  • J Med Chem. 2025 Dec 11;68(23):24869-24889. doi: 10.1021/acs.jmedchem.5c02638.
Elisabetta Armani 1,  Andrea Rizzi 1,  Daniela Miglietta 1,  Irene Bassanetti 1,  Francesco Amadei 1,  Giandomenico Brogin 1,  Carmelida Capaldi 1,  Fabio Rancati 1,  Chiara Carnini 1,  Sergio Xanxo Fernandez 1,  Maurizio Civelli 1,  Paola Puccini 1,  Marta Bellini 1,  Andrew Jennings 2,  Robert A Heald 2,  Lilian Alcaraz 2,  Jonathan M Sutton 2,  Harry Finch 3,  Mary Fitzgerald 3,  Craig Fox 3,  Gino Villetti 1
Affiliations

Affiliations

  • 1 Chiesi Farmaceutici S.p.A, Centro Ricerche, 43122 Parma, Italy.
  • 2 Charles River Laboratories, Harlow CM19 5TR, United Kingdom.
  • 3 Pulmagen Therapeutics, The Coach House, Slough SL1 8DF, United Kingdom.
PMID: 41307403 DOI: 10.1021/acs.jmedchem.5c02638
Abstract

The inhibitors of neutrophil Elastase (NE) have long attracted interest for the treatment of respiratory diseases. We report the breakthrough of a new potent, selective NE inhibitor with a 24 h duration of action: CHF-6333, is currently undergoing clinical studies for the inhaled treatment of bronchiectasis (BE). The story of the discovery project to identify novel small molecules that inhibit extracellular Elastase in the lung with prolonged activity is described. Medicinal chemistry investigation, supported by docking studies, led to N-quaternary compounds with an in vitro profile suitable for inhalatory administration. Compound 15 emerged from in vivo pharmacokinetic and pharmacodynamic studies, also showing safety and no off-target effects in vitro. Salt screening of different counterions, in conjunction with in vivo local irritancy testing, aided in the selection of compound 15-xinafoate (CHF-6333). Efficacy in a lung injury model and no findings in non-GLP toxicity studies promoted CHF-6333 as a clinical candidate.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z